Hemant S. Murthy, M.D.

Open

• A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study Of Lisaftoclax (APG-2575) In Combination With Azacitidine (AZA) In Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4). Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

  A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.

• A Phase 1, Open-Label, Dose-Escalation With Expansion Study Of SX-682 Alone And In Combination With Oral Or Intravenous Decitabine In Subjects With Myelodysplastic Syndrome Jacksonville, Fla.

  This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).